TABLE 3

Univariable and multivariable Cox proportional regression analysis for time to all-cause, nonelective hospitalisation at 1 year

Univariable analysisMultivariable analysis: Model 1#Multivariable analysis: Model 2#
HR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-value
4MGS m·s−10.03 (0.01–0.18)<0.0010.02 (0.01–0.14)<0.001
Slow 4MGS (reference: preserved 4MGS)3.97 (1.94–8.11)<0.0012.76 (1.16–6.58)0.02
Age years1.03 (0.97–1.09)0.34
Sex (reference: female)2.19 (0.67–7.22)0.204.33 (1.10–17.09)0.043.76 (1.03–13.70)0.045
Smoking status (reference: never-smoker)2.34 (0.96–5.69)0.06
FVC % pred0.98 (0.96–1.00)0.02
DLCO % pred0.96 (0.94–0.99)0.0030.96 (0.93–0.99)0.0050.96 (0.94–0.99)0.01
6MWD m0.99 (0.99–0.99)<0.0010.99 (0.99–1.00)0.09
Prescribed antifibrotic medication during the study period (reference: no)0.82 (0.40–1.65)0.57
Respiratory hospital admissions in previous year n1.19 (1.01–1.41)0.04
Chest infections in previous year n1.10 (0.93–1.31)0.260.02 (0.01–0.14)0.15

4MGS: 4-m gait speed; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWD: 6-min walk distance. Model 1: 4MGS (continuous format), age, sex, smoking status, FVC % pred, DLCO % pred, 6MWD, prescribed antifibrotic medication during the study period, number of hospital admissions in the previous year, number of chest infections in the previous year. Model 2: slow 4MGS (binary format), age, sex, smoking status, FVC % pred, DLCO % pred, 6MWD, prescribed antifibrotic medication during the study period, number of hospital admissions in the previous year, number of chest infections in the previous year. #: final model presented.